An open label randomised controlled study in elderly subjects with previously untreated acute myelogenous leukaemia [acute myeloid leukaemia], comparing treatment groups randomised to receive daunorubicin and cytarabine or daunorubicin, cytarabine and PSC-833 [valspodar].

Trial Profile

An open label randomised controlled study in elderly subjects with previously untreated acute myelogenous leukaemia [acute myeloid leukaemia], comparing treatment groups randomised to receive daunorubicin and cytarabine or daunorubicin, cytarabine and PSC-833 [valspodar].

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2012

At a glance

  • Drugs Cytarabine; Daunorubicin; Valspodar
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 08 May 2012 Additional lead trial centers identified as reported by Netherlands Trial Register.
    • 08 May 2012 Additional trial location added as reported by Netherlands Trial Register.
    • 08 May 2012 New source identified and integrated (NTR360: Netherlands Trial Register).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top